Filtered By:
Specialty: Internal Medicine
Drug: Coumadin
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 131 results found since Jan 2013.
Apixaban reduced stroke or systemic embolism in AF more than warfarin regardless of type or duration of AF.
PMID: 23856706 [PubMed - in process]
Source: Annals of Internal Medicine - July 16, 2013 Category: Internal Medicine Authors: Vazquez S, Rondina MT Tags: Ann Intern Med Source Type: research
Medical management of critical limb ischaemia: where do we stand today?
This article is protected by copyright. All rights reserved.
Source: Journal of Internal Medicine - June 26, 2013 Category: Internal Medicine Authors: Matthew A. Lambert, Jill J. F. Belch Tags: Review Source Type: research
Clinical outcomes with rivaroxaban in patients transitioned from vitamin k antagonist therapy: a subgroup analysis of a randomized trial.
CONCLUSION: The efficacy of rivaroxaban in VKA-experienced and VKA-naive patients was similar to that of the overall trial. There were more bleeding events within 7 days of study drug initiation with rivaroxaban, but after 30 days, rivaroxaban was associated with less bleeding in VKA-naive patients and similar bleeding in VKA-experienced patients. This information may be useful to clinicians considering a transition to rivaroxaban for patients receiving VKA therapy.
PRIMARY FUNDING SOURCE: Johnson & Johnson and Bayer HealthCare.
PMID: 23778903 [PubMed - in process]
Source: Annals of Internal Medicine - June 18, 2013 Category: Internal Medicine Authors: Mahaffey KW, Wojdyla D, Hankey GJ, White HD, Nessel CC, Piccini JP, Patel MR, Berkowitz SD, Becker RC, Halperin JL, Singer DE, Califf RM, Fox KA, Breithardt G, Hacke W Tags: Ann Intern Med Source Type: research
Warfarin for stroke prevention in atrial fibrillation: time to switch?
Source: International Journal of Clinical Practice - June 13, 2013 Category: Internal Medicine Authors: Y. Ahmad, G. Y. H. Lip Tags: Perspective Source Type: research
Potential impact of new oral anticoagulants on the management of atrial fibrillation‐related stroke in primary care
ConclusionThe clinical and economic benefits of the new oral anticoagulants, along with appropriate risk stratification, may enable a higher number of patients with AF to receive effective and convenient prophylaxis for stroke prevention.
Source: International Journal of Clinical Practice - April 28, 2013 Category: Internal Medicine Authors: K. Harris, J. Mant Tags: Review Article Source Type: research
Hospitalized patients with atrial fibrillation compared to those included in recent trials on novel oral anticoagulants: A population-based study.
CONCLUSION: In patients recently discharged from the hospital with the diagnosis of nonvalvular AF, warfarin use decreases and aspirin treatment increases with patients' age. These patients are older, more frequently female, and on multiple medications. The benefit of NOACs in these subjects needs to be confirmed in phase IV clinical studies.
PMID: 23528931 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - March 22, 2013 Category: Internal Medicine Authors: Joppi R, Cinconze E, Mezzalira L, Pase D, Poggiani C, Rossi E, Pengo V, Italian Horizon Scanning Project Tags: Eur J Intern Med Source Type: research
Thromboprophylaxis in heart failure patients with sinus rhythm: aspirin and warfarin lead to similar cardiovascular outcomes
Commentary on: Homma S, Thompson JL, Pullicino PM, et al.. WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012;366:1859–69. Context Chronic heart failure (CHF) is common, affecting 1–2% of the population and 10% of people >70 years. Patients with CHF have an increased risk of thromboembolism. Those with atrial fibrillation (AF) should receive warfarin but whether CHF patients with sinus rhythm (SR), whose risk is 1.5–3.5%,1 should receive thromboprophylaxis is unclear. Previous studies, Warfarin/Aspirin Study in Heart failure (warfarin, asp...
Source: Evidence-Based Medicine - March 19, 2013 Category: Internal Medicine Authors: Witte, K. K. A., Jamil, H. A. Tags: Epidemiologic studies, Drugs: cardiovascular system, Stroke, Ischaemic heart disease, Diabetes, Arrhythmias Therapeutics Source Type: research
Stroke prophylaxis in high-risk patients with atrial fibrillation: Rhythm vs. rate control strategy.
CONCLUSIONS: Anti-thrombotic prophylaxis in CHADS₂ ≥2 patients is different in subjects assigned to the Rhythm vs. the Rate control strategy, as well as reported reasons for warfarin non use. GPs do not know why warfarin is not used in a large percentage of cases, mainly in the rhythm control strategy group. Improving efforts should probably be differently tailored for patients assigned to the "rhythm" or the "rate" control strategy.
PMID: 23474251 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - March 5, 2013 Category: Internal Medicine Authors: Filippi A, Zoni-Berisso M, Ermini G, Landolina M, Brignoli O, D'Ambrosio G, Zingarini G, Pedrinazzi C Tags: Eur J Intern Med Source Type: research
Dabigatran associated with increased risk of acute coronary events
Commentary on: Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012;172:397–402. Context The novel oral anticoagulants, comprised of direct thrombin inhibitors (DTIs) (ie, dabigatran) and the factor Xa inhibitors (ie, rivaroxaban, apixaban and edoxaban), are revolutionising the way patients are anticoagulated. Recent years have witnessed a surge of trials evaluating these drugs in many clinical contexts. However, with such rapid uptake, it becomes critical to carefully evaluate safety data in order ...
Source: Evidence-Based Medicine - January 17, 2013 Category: Internal Medicine Authors: Kohli, P., Cannon, C. P. Tags: Electronic pages Source Type: research
Anticoagulants in Patients with Atrial Fibrillation and End-Stage Renal Disease
K. Scott Brimble, MD; Alistair J. Ingram, MD; John W. Eikelboom, MD; Robert G. Hart, MD
DOI: 10.3810/pgm.2012.11.2609
Abstract: Atrial fibrillation (AF) is a common cardiac arrhythmia and is associated with an increased risk for thromboembolic stroke. Anticoagulant therapy has been shown to reduce the risk for ischemic stroke in patients with AF; however, these studies have excluded patients with end-stage renal disease (ESRD). This review examines the relationships between ESRD, AF, and the use of anticoagulants to prevent ischemic stroke. Medline and Embase were used to identify relevant articles. Identified review...
Source: Postgraduate Medicine Online - December 26, 2012 Category: Internal Medicine Authors: admin Source Type: research
A Review of Oral Anticoagulants in Patients with Atrial Fibrillation
Arnold J. Greenspon, MD
DOI: 10.3810/pgm.2012.11.2608
Abstract: There is a high prevalence of atrial fibrillation in the United States, particularly in the elderly population. Patients with atrial fibrillation are at an increased risk of stroke and anticoagulant therapy is recommended. However, many eligible patients are not receiving therapy due to limitations and concerns related to the use of the vitamin K antagonist warfarin, such as slow onset of action, variable drug metabolism, risk of bleeding, and requirement for monitoring. Novel oral anticoagulants (NOACs) have been developed and may be used as an alternat...
Source: Postgraduate Medicine Online - December 26, 2012 Category: Internal Medicine Authors: admin Source Type: research
